Efficacy and Safety of Two Hair Supplements in Men With Androgenic Alopecia

Inclusion criteria

• Healthy male subjects
• Subjects of Caucasian ethnicity
• Subjects aged between 35 and 65 years (extremes included)
• Subjects with mild to moderate androgenetic alopecia, corresponding to the grade II to III vertex on Hamilton-Norwood scale
• Subjects with hair that is at least 5-7 cm long
• Subjects with visible grey or white hair
• Subjects registered with national health service
• Subjects certifying the truthfulness of the personal data disclosed to the Principal Investigator or designated personnel
• Subjects able to understand the language used in the investigation center and the information given by the Principal Investigator or designated personnel
• Subjects able to respect the instructions given by the Principal Investigator or designated personnel as well as able to respect the study constraints and specific requirements
• Subjects who commit not to change their daily routine or lifestyle during the study*
• Subjects on stable pharmacological therapy (except for the pharmacological therapy in the non-inclusion criteria) for at least one month without any changes expected or planned during the study
• Subjects informed about the test procedures who have signed a consent form and privacy agreement

• Subjects are asked not to change their usual hair hygiene and styling products (such as shampoo, conditioner, hair gel, hairspray, etc.) throughout the study

Exclusion criteria

• Subjects who do not meet the inclusion criteria
• Subjects with any acute, chronic, or progressive disease or condition that may interfere with the study data or that the Principal Investigator considers dangerous to the subject or incompatible with the requirements of the study **
• Subjects participating or planning to participate in other clinical trials
• Subjects who participated in a similar study without respecting an adequate washout period (at least one month)
• Subjects that have food intolerances or food allergies to ingredients of the study product
• Subjects under pharmacological treatments that are considered incompatible with the study requirement by the Principal Investigator ***
• Subjects who are currently using food supplement(s) and/or products with the same activity as the study product, or who haven't observed an adequate washout period (at least one month)
• Subjects admitted to a health or social facility
• Subjects planning a hospitalization during the study
• Subjects not able to be contacted in case of emergency
• Subjects deprived of freedom by administrative or legal decision or under guardianship
• Subjects who have or have had a history of alcohol or drug addiction
• Subjects with eating disorders (i.e. bulimia, psychogenic eating disorders, etc.)

• Including oncological diseases, diabetes, autoimmune diseases, acute inflammatory diseases, ongoing infectious diseases, and alopecia areata.

• Including corticosteroid drugs, biological drugs, and cytostatic drugs.